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Aim: The objective of this article is to evaluate the relationship between the changes in 
prescriptions of antiosteoporotic drugs (mainly the rapid fall in the use of bisphosphonates 
[BPs]) and standardized hip fracture (HF) rates over the period 2005–2008 in the Australian 
Capital Territory (ACT).
Methods: Annual sex- and age-specific HF rates (per 100,000 population) were determined and 
standardized using the Australian 2006 population census. Data on the annual prescriptions of 
BPs (mainly alendronate and risedronate), strontium ranelate, and hormone replacement therapy 
were obtained from the Australian Pharmaceutical Benefits Scheme (PBS) and Repatriation 
Australian Pharmaceutical Benefits Scheme (RPBS) databases.
Results: In the ACT, the peak annual number of prescriptions for BPs was observed in 2006. 
Following reports linking osteonecrosis of the jaw with BP use, the number of BP prescrip-
tions dropped by 14% in 2007–2008 compared with 2005, when the lowest HF rates were 
recorded. The reduction in BP prescriptions coincided with increased HF rates in females in 
2007 (+22.6%) and in 2008 (+25.2%) compared with 2005; in males, HF incidence declined 
by 6.6% and 16.7%, respectively. The proportion of filled prescriptions for strontium ranelate, 
risedronate, and alendronate in 2007–2008 was 1:8.4:15.5, indicating that BPs were the dominant 
antiosteoporotic drugs. There was an inverse statistically significant relationship between the 
total annual number of BP prescriptions and standardized HF incidence rates for the 10-year 
period 1999–2008.
Conclusion: Although currently there is no clear understanding of factors contributing to 
changing HF epidemiology, the available evidence suggests that much of the decline in HF 
rates is due to the use of BPs. The fall in the use of BPs is associated with an increase in HF 
rates in females, indicating that BPs should still be considered the first-line medications for the 
prevention and treatment of osteoporosis. Our results need to be confirmed in other populations 
and countries.
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Introduction
In the past decade, bisphosphonates (BPs) have become the cornerstone in the treatment 
of osteoporosis. Their effectiveness in reducing fracture risk, including hip fracture 
(HF), safety, and good tolerability, has been demonstrated in multiple randomized, 
placebo-controlled clinical studies.1–4 The use of these drugs has also been shown to be 
cost-effective for the prevention and treatment of fractures associated with osteoporosis 
in the older adult population.5–7 However, the effectiveness of BPs in the general 
population is less certain.8 In a community cohort of postmenopausal women at risk 
(bone mineral density [BMD] T-score #2, or prior fracture), the incidence of fractures Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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in patients who received BPs did not differ from those who 
did not.9 A recent study10 on HF prevention in long-term 
care concluded that there is little evidence to apply existing 
evidence on osteoporosis treatment to this population, as frail 
older adults are often neglected in clinical trials.
However, in the province of Ontario, Canada, a 
decrease in wrist fracture and HF rates from 1997 to 2003 
was associated with a significant increase in the number 
of BMD tests with dual-energy X-ray absorptiometry 
(DXA) and prescriptions of antiresorptive drugs (mainly 
etidronate).11 Similarly, an analysis of a large population 
of BP users in the United States who were followed for 
2 years demonstrated that adherence to BP therapy was 
associated with significantly fewer osteoporotic fractures, 
including HFs.12 In a previous ecologic study,13 we also 
found that, coincident with increased prescribing of BPs 
(in Australia, this treatment became widely available in 
2000), HF incidence rates progressively declined (statisti-
cally significant in females only), and the lowest rates were 
recorded in 2005.
When reports linking the use of BPs with osteonecrosis 
of the jaw (ONJ) were published, subsequent alarmist media 
coverage had a major effect on patient perceptions about the 
use of BPs, and widespread fear resulted in discontinuation 
of BP treatment.
The incidence of ONJ associated with oral BP treatment 
for osteoporosis has been estimated to be between ,14,14,15 
and 20–2816,17 in 100,000 patient-years of exposure. No cases 
of ONJ have been reported in clinical trials of alendronate, 
risedronate, and ibandronate for osteoporosis indications.18 
However, in patients with multiple myeloma, advanced 
cancer, and metastasis to the skeleton for whom BPs are used 
in high doses intravenously, the incidence of ONJ may be 
much higher (1 in 1000), specifically after dental procedures 
(up to 2%–12% at 36 months’ exposure).19–22
Despite the lack of convincing evidence for a direct 
causative relationship between ONJ and BPs (especially 
with low doses used in osteoporosis), a very low incidence 
of ONJ, and its poorly understood and likely multifactorial 
pathogenesis,4,16,19,23–26 the use of BPs in Australia is 
decreasing.
The potential impact of this drop in BP use on the 
incidence of osteoporotic fractures, including HF, is 
unknown. From the societal perspective, such data are impor-
tant for a realistic assessment of the real-world effectiveness 
of current antiosteoporotic and fracture prevention strategies. 
The aim of this study was to evaluate the relationship between 
the changes in prescriptions of antiosteoporotic drugs 
(mainly the rapid fall in the use of BPs) and standardized 
HF rates over the period 2005–2008.
Materials and methods
The Australian Capital Territory (ACT) region is well suited 
for an epidemiological study because all HFs occurring in 
this area are treated at the Canberra Hospital. In 2008, the 
ACT had a total population of 352,189 people with 15.1% 
aged 60 years and above.27 The study was approved by the 
ACT Human Research Ethics Committee. All the data used 
for the analysis were anonymous and confidential.
Methods of data collection on HF incidence and 
antiosteoporotic drugs used were presented in detail in our 
previous study, which covered the years 1994/95 to 2005/06.13 
In brief, we utilized the Canberra Hospital electronic adminis-
trative database to identify patients discharged with a diagno-
sis of HF and excluded all readmissions and reoperations, as 
well as patients with pathological HF (primary or metastatic 
bone cancer, multiple myeloma, or Paget’s disease). In this 
study, only cervical and trochanteric fractures of the proximal 
femur were included, and subtrochanteric and shaft fractures 
were excluded. Annual sex- and age-specific incidence rates 
(per 100,000 population) were determined using data from 
the Australian Bureau of Statistics. Annual HF incidence 
rates were age- and sex-standardized by the direct method 
using the Australian 2006 population census as standard. 
Standardization provides estimates that can be compared 
directly from one year to another without the confounding 
effects of the aging of the population and changes in sex 
distribution.
Data on the annual prescriptions of BPs (mainly alendronate 
and risedronate), strontium ranelate (approved in Australia in 
2006), and hormone replacement therapy (HRT oral or trans-
dermal estrogen only or combined estrogen–progesterone 
prescriptions) were obtained from the Australian Pharma-
ceutical Benefits Scheme (PBS) and Repatriation Australian 
Pharmaceutical Benefits Scheme (RPBS) databases.28 All 
doses of the aforementioned drugs were considered.
The prescriptions analyzed in this dataset (provided under 
government subsidy) are restricted to two groups: 1) patients 
aged 70 years or above with demonstrated low BMD (BMD 
T-score ,−3), and 2) patients with demonstrated fracture due 
to minimal trauma. Therefore, it can be reasonably postulated 
that most patients receiving BPs were older adults who are at 
high risk of fracture. Although private (non-PBS) prescriptions 
are available, the numbers are low. A marked increase occurred 
from 2001 when BPs became available as PBS prescriptions. 
Because vitamin D and calcium supplements are not covered Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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by PBS/RPBS and use of raloxifene and parathyroid hormone 
(PTH) analogs (teriparatide) was minimal, these preparations 
were not included in the analysis.
Statistical analysis
Statistical analysis was performed using Stata Version 10 
(Stata Corp, College Station, TX, USA). The relationship 
between HF incidence rate and antiosteoporotic drugs 
use was examined by calculation of Pearson’s correlation 
coefficient after logarithmic (log) transformation of variables 
with skew distribution and by linear regression analysis. All 
statistical tests were performed at the two-sided P , 0.05 
level of significance.
Results
Incidence of HF
Over the 2006–2008 period, the ACT population aged $60 
years increased by 13.9% in women and 14.9% in men, and 
the number of subjects $85 years, which represented 1.2% 
of the total ACT population (34.6% male, 65.36% female), 
increased by 15.4% in women and by 27.3% in men.
In our region during the last 3 years (2006–2008), there 
were 494 HFs in older adults ($60 years), and 72.7% occurred 
in females. Among females, 53.1% were aged $85 years and, 
among males, 35.6% were aged $85 years. In females, the 
annual numbers of HFs and HF rates during this period 
progressively increased compared with 2005 (Table 1). The 
crude HF rates among females increased by 11.2% in 2006, 
16.2% in 2007, and 22.6% in 2008. The age-specific HF 
Table  1  Annual  absolute  number  of  hip  fractures,  age-  and 
sex-specific and standardized incidence rates of hip fractures in 
subjects 60 years of age and older
Year Sex N (%) Rate/100,000 person-years
2005 F 91 (68.4) 581.4a 426.9b
M 42 (31.6) 206.6a 227.6b
Total 133 (100.0) 300.9a 334.4b
2006 F 105 (68.6) 424.1a 481.8b
M 48 (31.4) 225.3a 244.8b
Total 153 (100.0) 322.1a 371.7b
2007 F 121 (72.9) 443.3a 506.2b
M 45 (27.1) 189.3a 212.6b
Total 166 (100.0) 324.9a 364.9b
2008 F 133 (76.0) 467.5a 534.5b
M 42 (29.0) 169.6a 189.5b
Total 175 (100.0) 328.9a 369.6b
Change (%) 
from 2005  
to 2008
F 42 (46.2%) +86.1 (22.6%)a +107.6 (25.2%)b
M 0 −37.0 (−17.9%)a −38.1 (−16.7%)b
Total 42 (31.6%) +28.0 (9.3%)a +35.2 (10.5%)b
Notes: aannual age- and sex-adjusted rates (crude); bannual rates standardized to 
the 2006 Australian population.
Abbreviations: F, female; M, male.
rates in females increased within each group, with the largest 
absolute increase in those aged $85 years (from 2384.3 to 
2567.0/100,000 person-years or +182.7 [7.7%]/100,000 
person-years from 2007 to 2008) and the largest percent-
age increase in the age group 70–74 years (from 186.0 to 
245.4/100,000 person-years or +31.9% in 2008 compared 
with 2007). The age-standardized HF rates, which elimi-
nate the effects of the changes in the population structure 
over time, demonstrate a slightly higher increase: 12.9% 
in 2006, 22.6% in 2007, and 25.2% in 2008 compared 
with 2005.
Among males, the absolute numbers of HFs did not 
change, but the age-specific rates decreased in 2007 
(−8.4%) and 2008 (−17.9%) compared with those in 
2005. The age-specific HF rates in 2008 compared with 
2007 decreased in those aged 75–79 years (from 348.1 
to 170.5 [−177.6]/100,000 person-years, or −51.0%) 
and in the group 80–84 years of age (from 589.1 to 
388.2 [−200.9]/100,000 person-years, or −34.1%), but 
increased in those aged $85 years (from 854.1 to 1276.0 
[+421.9]/100,000 person-years, or +49.4%) and 60–74 years 
of age (from 48.7 to 57.9, or +9.2 [+18.9%]/100,000 
 person-years). For males, the age-standardized HF rates in 
2006 were slightly higher than in 2005 (+7.6%) but lower 
in 2007 (−6.6%) and 2008 (−16.7%).
Overall in 2008 compared with 2005, age-adjusted HF 
rates (for females and males) increased by 9.3%, and age-
standardized rates increased by 10.5%. The female to male 
ratio in the standardized HF rates changed from 1.88 in 
2005 to 2.82 in 2008, indicating a pronounced increase in 
HF incidence in women.
Use of BPs and other antiosteoporotic 
medications and HF incidence
In the ACT, the peak annual number of prescriptions for 
BPs was observed in 2006. From 2006 to 2008, there has 
been a steady decline in the number of filled prescriptions 
for BPs, from 51,271 (2006) to 45,674 (−10.9%) in 2008. 
In total, the number of prescriptions dispensed in the ACT 
over 2007–2008 dropped by 6927 or by 14% compared with 
2005, when the lowest HF rates were recorded (Figure 1). 
Over the same period, the number of HRT prescriptions also 
continued to decline (−7.6% in 2007 and −12.1% in 2008 
compared with 2006). The absolute number of prescriptions 
for strontium ranelate increased (from 28 in 2006 to 2370 in 
2008), but this constitutes only 4.02% of the number of BP 
prescriptions. The proportion of filled prescriptions for stron-
tium ranelate, risedronate, and alendronate in 2007–2008 Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Figure 1 Age-adjusted and standardized to 2006 Australian population rates of hip fracture in women and men aged ≥60 years and prescriptions of bisphosphonates, 
strontium ranelate, and hormone replacement therapy in the Australian Capital Territory from 1999 to 2008.
Table 2 Linear regression analysis between the number of bispho-
sphonate  prescriptions  (×103)  and  age-standardized  hip  fracture 
rates (per 100,000 person-years) in the elderly in 1999–2008 in 
the Australian Capital Territory
Coefficient SE 95% CI P value R2 adjusted
Females −60.43 1.054 −8.473 to  
−3.613
,0.001 0.780
Males −1.554 0.403 −2.882 to  
−1.026
0.001 0.715
Total −4.188 0.616 −5.610 to  
−2.767
,0.001 0.834
Abbreviations: SE, standard error; CI, confidence interval.
was 1:8.4:15.5, indicating that BPs were the dominant 
antiosteoporotic drugs. In 2007–2008 compared with 2005, 
among those aged $60 years, the absolute number of HFs 
increased by 75 (all females), and the number of prescriptions 
for BPs decreased by 6927. This corresponds to a drop of 
92.4 prescriptions per one ‘extra’ (unexpected) HF.
Figure 1 shows that changes in the use of antiosteoporotic 
drugs, especially BPs, were accompanied by inverse changes 
in standardized HF rates, particularly in females. After 2001, 
when BP prescriptions started increasing, the HF rates began 
to decrease, and this downward trend continued up to 2005, 
coinciding with a significant increase in BP use. Over the 
period from 2001 to 2005, the HF incidence declined in total 
by 42.6% (from 583.0 to 248.6/100,000 person-years), 54.1% 
in females (from 831.7 to 381.4/100,000 person-years) and 
23.2% in males (from 296.5 to 227.6/100,000 person-years). 
The reduction in BP prescriptions observed in 2007–2008 
was associated with increased HF rates in females, whereas 
male HF rates continued to decline.
When analyzing the relationship between age-standardized 
HF rates and BP prescriptions, we calculated Pearson’s 
correlation coefficient and found a significant inverse relation-
ship between the total annual number of BP prescriptions (log-
transformed) and HF rates in the total older adult population 
(r = −0.735; P = 0.015), in females (r = −0.668; P = 0.027), and 
in males (r = −0.776; P = 0.008). No significant correlation was 
found for strontium ranelate. Unfortunately, PBS/RPBS data 
do not include the gender of the population filling prescriptions 
for antiosteoporotic medications, so we were unable to analyze 
the use of BPs separately by females and males.
Linear regression analysis of the relationship between the 
number of BP prescriptions and standardized HF rates from 
1999 to 2008 confirmed the inverse relationship (Table 2). 
As illustrated in Figure 2, higher BP use was associated with 
significantly lower HF rates.
Discussion
The main finding of this ecologic study is an inverse statis-
tically significant relationship between use of osteoporosis 
treatment, namely the total annual number of BP prescrip-
tions, and standardized HF incidence rates for the 10-year 
period 1999–2008.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Over the last decade, advances in molecular and cellular 
biology of bone remodeling have revealed new targets for 
and novel pharmacological approaches to therapies for 
osteoporosis. Newer agents include strontium ranelate 
(capable of both inhibiting bone resorption and increas-
ing bone formation),29,30 new-generation selective estrogen 
receptor modulators lasofoxifene31 and bazedoxifene,32 
anabolic agents (PTH and its analogs, monoclonal antibody 
to sclerostin),33–36 and antiresorptive agents such as RANK 
signaling inhibitors (denosumab), cathepsin K inhibitors 
(odanacatib, balicatib, and relacatib), and antagonists of 
α(v)β(3) integrin (L-000845704).34,37–39 Although the newer 
and emerging therapies as well as combined treatments 
(eg, with alfacalcidol)2 may be more potent and target-
specified,2,33,37,40,41 currently, nitrogen-containing BPs, anti-
resorptive agents shown to reduce fracture risk by ∼50% at 
best,42 remain the mainstay for pharmacological treatment 
of osteoporosis.4,18,43–46 The antiresorptive action of BPs 
as a class results from both reduced osteoclastic activity 
(by inhibiting an enzyme farnesyl pyrophosphate synthase) 
and affinity for bone mineral, but the antiresorptive potency 
and binding affinity differ among the compounds.
We focused on the BPs because the prevalence of use 
of other antiosteoporotic drugs over this period was too low 
to detect an effect on HF incidence. After 2000, when BPs 
became widely available in Australia, the number of prescrip-
tions steadily increased up to 2006. Between 2001 and 2005, 
the HF incidence declined in older females ($60 years) by 
54.1%, in males by 23.2%, and in total by 42.6%. These find-
ings are in agreement with those reported from Canada:11 a 
decline of HF rates with a steady increase in etidronate use 
between 1996 and 2003.
The new and intriguing observation of this study is that 
the substantial fall in BP use (following reports on ONJ 
associated with BPs) since 2006 coincides with increased 
standardized HF rates in females in 2007 (+22.6%) and in 
2008 (+25.2%) compared with 2005, whereas, in males, 
HF incidence declined in the same period. Older females 
are known to comprise the majority of BP users, whereas 
male osteoporosis is much less frequently recognized and 
treated.47,48 Our observations are in line with data showing 
an inverse relation between adherence to BP and fracture 
rate. High adherence to BP therapy was associated with a 
23% reduction in HF rates,49 and poor compliance resulted 
in a 28% increased HF risk.50 A recently published Aus-
tralian study concluded that, in 2008, a 13.2% estimated 
reduction in the number of BP prescriptions may have 
resulted in 70 (+16.9%) HFs and 14 deaths.51 Importantly, 
BPs not only effectively prevent fragility fractures but also 
improve quality of life52 and reduce the risk of breast cancer 
in postmenopausal women,53,54 as well as reduce all-cause 
mortality.55–57
The fact that reduction in BP prescriptions was 
followed by an increase in HF rates in females, along with 
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Figure 2 The relationship between the total annual number of prescriptions (×103) 
for bisphosphonates and age-standardized hip fracture rates (per 100,000 person-
years) in A) females, B) males, and C) the total elderly population in the Australian 
Capital Territory (1999–2008). Regression lines with 95% confidence intervals.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
360
Fisher et al
the previously observed decline in HF rates when BP use 
rapidly increased, does not necessarily establish a causal 
connection between the two. Other factors may also have 
contributed to the short-term changes in HF incidence rates. 
Indeed, trends toward decreasing HF rates were observed 
in some countries (United States, Canada, and Sweden) 
before widespread availability of current antiosteoporotic 
medications.8,58–60 No consistent changes or even increasing 
HF trends were recently reported in other developed countries 
(Germany, Austria, Finland, Switzerland, and Japan),61–65 
and some found declining HF incidence only in the new 
millennium,11,61,66,67 although none of these studies, except 
one,11 provided information on BP use.
The continuing fall in the use of HRT since 2001 is 
unlikely to account for the increase in HF incidence in 
females in 2007–2008, as in the previous period (2001–2005), 
despite HRT prescriptions having decreased by half and HF 
rates having declined by 54.1%.
Different patterns in HF rates seen in males and females 
may argue against the role of BPs. In contrast to some 
recent studies61 reporting no downward trend in the HF 
rates in males, but in accordance with others,59 we found a 
reduction in HF incidence in males in 2007–2008 despite 
the drop in BP prescriptions. This is difficult to interpret. 
As men are rarely treated for osteoporosis, the reduction 
in use of BPs may be too small to lead to a detectable 
decrease in HF rates. Other factors possibly associated 
with a decrease in HF rates in males may include over-
weight and obesity, declining smoking rates,68 and a birth 
cohort effect.69 These explanations are still hypothetical. 
The complex relationship between HF and gender requires 
further investigations.
This study has certain limitations in addition to its 
ecologic design. No information was available on individual 
demographic and clinical characteristics of BP users. 
Similarly, the proportion of patients receiving adequate 
antiosteoporotic therapy (including calcium and vitamin D 
supplementation) is unknown. There is also a possibility that 
the medication was prescribed but not taken. On the other 
hand, because of the remaining effect of BP on fracture risk 
after cessation of treatment,70,71 it is likely that a short-term 
study, like ours, underestimates the impact of the current 
fall in BP use on HF rates. Despite these limitations, our 
ecological analysis provides strong support for the antifrac-
ture effectiveness of BPs in real-world practice.
In conclusion, although currently there is no clear 
understanding of factors contributing to changing HF 
epidemiology, the available evidence suggests that much of 
the decline in HF rates is due to the use of BPs. A fall in the 
use of BPs is associated with increased HF rates in females, 
indicating that BPs should still be considered the first-line 
medications for the prevention and treatment of osteoporosis. 
Our results need to be confirmed in other populations and 
countries.
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